The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 21, 2016

Filed:

Jul. 25, 2012
Applicants:

Le Cong, Cambridge, MA (US);

Ann Marie Egloff, Pittsburgh, PA (US);

Levi A. Garraway, Newton, MA (US);

Jennifer Rubin Grandis, Pittsburgh, PA (US);

Eric S. Lander, Cambridge, MA (US);

Nicholas Stransky, Boston, MA (US);

Aaron D. Tward, Boston, MA (US);

Feng Zhang, Cambridge, MA (US);

Inventors:

Le Cong, Cambridge, MA (US);

Ann Marie Egloff, Pittsburgh, PA (US);

Levi A. Garraway, Newton, MA (US);

Jennifer Rubin Grandis, Pittsburgh, PA (US);

Eric S. Lander, Cambridge, MA (US);

Nicholas Stransky, Boston, MA (US);

Aaron D. Tward, Boston, MA (US);

Feng Zhang, Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/85 (2006.01); A61K 38/16 (2006.01); A61K 38/46 (2006.01); A61K 45/06 (2006.01); C07K 14/47 (2006.01); C12N 9/22 (2006.01); C12N 15/90 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/164 (2013.01); A61K 38/465 (2013.01); A61K 45/06 (2013.01); C07K 14/4703 (2013.01); C07K 14/4705 (2013.01); C12N 9/22 (2013.01); C12N 15/907 (2013.01); A61K 48/005 (2013.01); C07K 2319/00 (2013.01); C07K 2319/70 (2013.01); C07K 2319/71 (2013.01); C07K 2319/80 (2013.01); C12N 2710/20011 (2013.01); C12N 2800/22 (2013.01); C12N 2999/007 (2013.01);
Abstract

The present invention provides methods related to the treatment of head and neck squamous cell carcinoma (HNSCC) and its associated premalignant lesions. In particular, the invention features methods which may specifically target HNSCC-associated genes and alter gene expression to treat or alleviate a symptom of HNSCC, or its related premalignant lesions. These methods may involve decreasing the function of an HNSCC-associated gene with aberrant gain-of-function; or increasing the function of an HNSCC-associated gene with aberrant loss-of-function.


Find Patent Forward Citations

Loading…